AR061317A1 - Agentes para prevenir o tratar enfermedades inflamatorias - Google Patents
Agentes para prevenir o tratar enfermedades inflamatoriasInfo
- Publication number
- AR061317A1 AR061317A1 ARP070102522A ARP070102522A AR061317A1 AR 061317 A1 AR061317 A1 AR 061317A1 AR P070102522 A ARP070102522 A AR P070102522A AR P070102522 A ARP070102522 A AR P070102522A AR 061317 A1 AR061317 A1 AR 061317A1
- Authority
- AR
- Argentina
- Prior art keywords
- mouse
- model
- inflammatory diseases
- neutralizing antibody
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Nuevos agentes para prevenir o tratar enfermedades inflamatorias que comprenden un antagonista de NR 10 como ingrediente activo. Los inventores de la presente obtuvieron, a partir de una biblioteca de anticuerpos humanos de fagos, un anticuerpo neutralizante anti-NR 10 de raton que expresa al clon BM095 que presenta una fuerte actividad supresora de la proliferacion en un sistema de ensayo de proliferacion celular Ba/F3 dependiente de IL-31. Cuando se administraba este anticuerpo neutralizante anti-NR 10 de raton a ratones NC/Nga, un modelo de dermatitis atopica que es un modelo de dermatitis cronica en raton debida a aplicaciones repetidas de cloruro de picrilo, un modelo de raton de artritis reumatoide y un modelo de raton de osteoartritis, se observo un efecto significativo de supresion de los síntomas. Esto revelo que el anticuerpo neutralizante anti-NR 10 efectivamente es eficaz como agente terapéutico para enfermedades inflamatorias. Además, los inventores de la presente obtuvieron con éxito un anticuerpo neutralizante anti-NR 10 humano, lo que proporciona agentes terapéuticos extremadamente utiles con aplicaciones clínicas prácticas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006160096 | 2006-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061317A1 true AR061317A1 (es) | 2008-08-20 |
Family
ID=38801569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102522A AR061317A1 (es) | 2006-06-08 | 2007-06-08 | Agentes para prevenir o tratar enfermedades inflamatorias |
Country Status (25)
Country | Link |
---|---|
US (2) | US9028821B2 (es) |
EP (2) | EP2047863B1 (es) |
JP (1) | JP5043008B2 (es) |
KR (3) | KR101557603B1 (es) |
CN (2) | CN101500608A (es) |
AR (1) | AR061317A1 (es) |
AU (1) | AU2007255753B2 (es) |
BR (1) | BRPI0712426B1 (es) |
CA (1) | CA2654623C (es) |
CL (1) | CL2007001665A1 (es) |
DK (1) | DK2047863T3 (es) |
ES (2) | ES2429407T3 (es) |
IL (1) | IL195361A0 (es) |
MX (1) | MX2008015568A (es) |
MY (1) | MY157796A (es) |
NO (1) | NO344849B1 (es) |
NZ (1) | NZ572888A (es) |
PE (1) | PE20080333A1 (es) |
PL (1) | PL2047863T3 (es) |
PT (1) | PT2047863E (es) |
RU (1) | RU2511406C2 (es) |
SI (1) | SI2047863T1 (es) |
TW (1) | TWI419703B (es) |
UA (1) | UA100116C2 (es) |
WO (1) | WO2007142325A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2339843T3 (es) * | 1999-06-02 | 2010-05-26 | Chugai Seiyaku Kabushiki Kaisha | Proteina receptora de hematopoyetina novedosa, nr10. |
ES2254224T3 (es) * | 1999-09-27 | 2006-06-16 | Chugai Seiyaku Kabushiki Kaisha | Nueva proteina del receptor de hematopoyetina, nr12. |
WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
EP4342995A2 (en) | 2006-03-31 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
DK2047863T3 (da) | 2006-06-08 | 2013-09-16 | Chugai Pharmaceutical Co Ltd | Middel til forebyggelse eller behandling af inflammatoriske sygdomme |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
MX337081B (es) * | 2007-12-05 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-nr10 y su uso. |
CN101939025B (zh) * | 2007-12-05 | 2015-03-25 | 中外制药株式会社 | 搔痒症治疗药 |
EP3211010A1 (en) * | 2007-12-21 | 2017-08-30 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r) - 173 |
KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항nr10 항체 및 그의 이용 |
JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
MX355060B (es) | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea. |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
PT3004167T (pt) | 2013-05-30 | 2018-11-13 | Kiniksa Pharmaceuticals Ltd | Proteínas de ligação ao antigénio do recetor da oncostatina m |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
MA41294A (fr) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
EP3233921B1 (en) | 2014-12-19 | 2021-09-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
TW202327654A (zh) | 2015-04-14 | 2023-07-16 | 日商中外製藥股份有限公司 | 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物 |
KR102641898B1 (ko) | 2015-04-14 | 2024-02-27 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
JP6845973B1 (ja) | 2019-11-20 | 2021-03-24 | 中外製薬株式会社 | 抗体含有製剤 |
US20230391878A1 (en) | 2020-09-01 | 2023-12-07 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
CN112552396B (zh) * | 2020-12-30 | 2022-07-12 | 河南中泽生物工程有限公司 | 抗非洲猪瘟病毒p54蛋白单克隆抗体、制备方法及应用 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
JPS63149900A (ja) | 1986-12-15 | 1988-06-22 | Toshiba Corp | 半導体メモリ |
JP2898064B2 (ja) | 1989-08-03 | 1999-05-31 | 忠三 岸本 | ヒトgp130蛋白質 |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
GB9016440D0 (en) | 1990-07-26 | 1990-09-12 | Elopak Systems | A laminate |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
BR9204244A (pt) | 1992-10-26 | 1994-05-03 | Cofap | Ferro fundido cinzento |
CZ140195A3 (en) | 1992-12-01 | 1996-06-12 | Protein Desing Labs | Humanized antibodies reacting with l-selectin |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
FR2729855A1 (fr) | 1995-01-26 | 1996-08-02 | Oreal | Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AUPN481295A0 (en) | 1995-08-16 | 1995-09-07 | Medvet Science Pty. Ltd. | Agonists of haemopoietic growth factors |
WO1997010354A1 (en) * | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
AUPN564195A0 (en) | 1995-09-26 | 1995-10-19 | Walter And Eliza Hall Institute Of Medical Research, The | A novel haemopoietin receptor and genetic sequences encoding same |
WO1997015663A1 (en) | 1995-10-23 | 1997-05-01 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
US6642360B2 (en) | 1997-12-03 | 2003-11-04 | Genentech, Inc. | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
CN1241944A (zh) | 1996-12-05 | 2000-01-19 | 乔治敦大学 | 具有抗病毒活性的鼠尾草种类的提取物 |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
JPH11101542A (ja) | 1997-09-29 | 1999-04-13 | Sanyo Electric Co Ltd | 冷蔵庫 |
US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
CA2326755A1 (en) | 1998-04-30 | 1999-11-04 | Tanox, Inc. | G-csf receptor agonist antibodies and screening method therefor |
FR2780062B1 (fr) | 1998-06-17 | 2000-07-28 | Rhone Poulenc Rorer Sa | Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations |
WO1999067290A1 (fr) | 1998-06-24 | 1999-12-29 | Chugai Research Institute For Molecular Medicine, Inc. | Nouvelles proteines receptrices d'hemopoïetine |
ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
DK1181366T4 (da) | 1999-06-01 | 2013-09-23 | Merck Sharp & Dohme | Mammale receptorproteiner, beslægtede reagenser og fremgangsmåder |
US20030082734A1 (en) | 1999-06-01 | 2003-05-01 | Dowling Lynette M. | Mammalian receptor proteins; related reagents and methods |
ES2339843T3 (es) * | 1999-06-02 | 2010-05-26 | Chugai Seiyaku Kabushiki Kaisha | Proteina receptora de hematopoyetina novedosa, nr10. |
ES2254224T3 (es) | 1999-09-27 | 2006-06-16 | Chugai Seiyaku Kabushiki Kaisha | Nueva proteina del receptor de hematopoyetina, nr12. |
ES2307618T3 (es) * | 2000-05-10 | 2008-12-01 | Schering Corporation | Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados. |
CN1326880A (zh) | 2000-06-06 | 2001-12-19 | 周伟中 | 双层站台火车站 |
WO2002000721A2 (en) | 2000-06-26 | 2002-01-03 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
AU2318202A (en) | 2000-10-06 | 2002-04-15 | Immunex Corp | Hematopoietin receptors hpr1 and hpr2 |
WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
WO2002081522A1 (fr) | 2001-04-05 | 2002-10-17 | Immuno-Biological Laboratories Co., Ltd. | Anticorps dirigé contre l'ostéopontine, et son utilisation |
BR0306979A (pt) | 2002-01-18 | 2004-11-23 | Zymogenetics Inc | Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente |
AU2003280410B8 (en) * | 2002-01-18 | 2009-04-23 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
SI1485477T1 (sl) | 2002-02-25 | 2009-10-31 | Genentech Inc | Novi citokinski receptor GLM-R tipa 1 |
CA2483909A1 (en) | 2002-05-01 | 2003-11-13 | Schering Aktiengesellschaft | Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
TW200407335A (en) | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
KR100499989B1 (ko) | 2002-12-27 | 2005-07-07 | 네오바이오다임 주식회사 | 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법 |
US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
US20040223970A1 (en) * | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
ES2527414T3 (es) | 2003-03-04 | 2015-01-23 | Alexion Pharmaceuticals, Inc. | Método para el tratamiento de una enfermedad autoinmune mediante la inducción de la presentación de antígeno mediante células presentadoras de antígeno que inducen tolerancia |
EA009124B1 (ru) | 2003-03-24 | 2007-10-26 | Займоджинетикс, Инк. | Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении |
JP5452835B2 (ja) | 2003-07-15 | 2014-03-26 | 中外製薬株式会社 | 形質転換細胞によるIgMの産生とその定量方法 |
AU2005259992A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune, Llc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
AU2006207945B2 (en) | 2005-01-28 | 2012-02-09 | Zymogenetics, Inc. | Homogeneous preparations of IL-31 |
WO2006088855A1 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
EP1856539B1 (en) | 2005-02-14 | 2015-10-21 | ZymoGenetics, Inc. | Methods of predicting therapeutic response in atopic dermatitis to il-31 antagonists |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
ES2561628T3 (es) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y métodos de uso |
EP3348639A3 (en) | 2005-06-10 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Sc(fv)2 site-directed mutant |
CA2636288C (en) * | 2006-01-10 | 2015-02-24 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists |
RU2520088C2 (ru) | 2006-01-12 | 2014-06-20 | Алексион Фармасьютикалз, Инк. | Антитела к ох-2/сd200 и их применение |
MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
DK2047863T3 (da) | 2006-06-08 | 2013-09-16 | Chugai Pharmaceutical Co Ltd | Middel til forebyggelse eller behandling af inflammatoriske sygdomme |
ES2415655T3 (es) * | 2006-06-15 | 2013-07-26 | The Board Of Trustees Of The University Of Arkansas | Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina |
EP2069404B1 (en) * | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
EP2059534B1 (en) | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
EP2138576A4 (en) | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
AR068564A1 (es) | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti- receptor de il-6 (interleuquina 6) |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
MX337081B (es) | 2007-12-05 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-nr10 y su uso. |
CN101939025B (zh) * | 2007-12-05 | 2015-03-25 | 中外制药株式会社 | 搔痒症治疗药 |
JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
-
2007
- 2007-06-08 DK DK07744945.2T patent/DK2047863T3/da active
- 2007-06-08 CL CL2007001665A patent/CL2007001665A1/es unknown
- 2007-06-08 RU RU2008152827/10A patent/RU2511406C2/ru active
- 2007-06-08 WO PCT/JP2007/061625 patent/WO2007142325A1/ja active Application Filing
- 2007-06-08 KR KR1020147017820A patent/KR101557603B1/ko active IP Right Grant
- 2007-06-08 KR KR1020097000236A patent/KR20090024243A/ko not_active IP Right Cessation
- 2007-06-08 SI SI200731328T patent/SI2047863T1/sl unknown
- 2007-06-08 UA UAA200814956A patent/UA100116C2/ru unknown
- 2007-06-08 TW TW096120709A patent/TWI419703B/zh active
- 2007-06-08 EP EP07744945.2A patent/EP2047863B1/en active Active
- 2007-06-08 CN CNA2007800296028A patent/CN101500608A/zh active Pending
- 2007-06-08 MX MX2008015568A patent/MX2008015568A/es active IP Right Grant
- 2007-06-08 PE PE2007000716A patent/PE20080333A1/es not_active Application Discontinuation
- 2007-06-08 NZ NZ572888A patent/NZ572888A/en unknown
- 2007-06-08 ES ES07744945T patent/ES2429407T3/es active Active
- 2007-06-08 PL PL07744945T patent/PL2047863T3/pl unknown
- 2007-06-08 KR KR1020157020982A patent/KR20150091545A/ko not_active Application Discontinuation
- 2007-06-08 AR ARP070102522A patent/AR061317A1/es not_active Application Discontinuation
- 2007-06-08 MY MYPI20084967A patent/MY157796A/en unknown
- 2007-06-08 AU AU2007255753A patent/AU2007255753B2/en active Active
- 2007-06-08 ES ES11169972.4T patent/ES2544888T3/es active Active
- 2007-06-08 EP EP11169972.4A patent/EP2371393B1/en active Active
- 2007-06-08 JP JP2008520634A patent/JP5043008B2/ja active Active
- 2007-06-08 BR BRPI0712426-0A patent/BRPI0712426B1/pt active IP Right Grant
- 2007-06-08 CA CA2654623A patent/CA2654623C/en active Active
- 2007-06-08 CN CN201310164586.0A patent/CN103272232B/zh active Active
- 2007-06-08 US US12/303,684 patent/US9028821B2/en active Active
- 2007-06-08 PT PT77449452T patent/PT2047863E/pt unknown
-
2008
- 2008-11-18 IL IL195361A patent/IL195361A0/en active IP Right Grant
-
2009
- 2009-01-07 NO NO20090093A patent/NO344849B1/no unknown
-
2015
- 2015-04-07 US US14/680,154 patent/US9745378B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061317A1 (es) | Agentes para prevenir o tratar enfermedades inflamatorias | |
BRPI0821145B8 (pt) | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido | |
BRPI0608109A2 (pt) | tratamento de distúrbios ósseos | |
ECSP13012618A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
BR112013023724A2 (pt) | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento | |
BR112016013547A2 (pt) | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos | |
BR112016013207A2 (pt) | administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais | |
MX2015004644A (es) | Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados. | |
BR112013002601A2 (pt) | corticosteróides para o tratamento de dor em articulação | |
BR112012025390B8 (pt) | Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto | |
GT201400069A (es) | Composiciones farmaceuticas | |
AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
BR112015022896A2 (pt) | drogas de alta penetração e suas composições para o tratamento de doenças de parkinson | |
BR112015017525A2 (pt) | peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado | |
BR112021022789A2 (pt) | Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a | |
BR112018014467A2 (pt) | tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças | |
BR112017002878A2 (pt) | distribuição coordenada de tratamento de copd | |
IN2013DE00228A (en) | “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof” | |
BR112013024828A2 (pt) | "derivados de sulfamida tendo um grupo adamantil e seu sal farmaceuticamente aceitável, agente inibitório a 11?-hsd1, e composição farmacêutica". | |
MY174186A (en) | Use of an isopropanol-containing solution to combat caliciviridae | |
Becze | P6 Acupressure Can Help Patients Self-Manage Chemotherapy-Induced Nausea. | |
TH151349A (th) | การใช้สารยับยั้ง dgat1 | |
Svid et al. | New potential of rheumatic diseases immunobiological therapy | |
Chirivi et al. | Mode of Action of Therapeutic Anti-Citrullinated Protein Antibodies Revealed: Inflammation Reduction Due to Inhibition of Netosis | |
ES2446215R2 (es) | Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |